#1Skan SKAN Group Investor Presentation November 2023#2Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This presentation (the "Presentation"), contains information regarding SKAN Group AG (the "Company") and each of its subsidiaries and affiliates (the "Group"). The information and opinions contained in this Presentation do not purport to be comprehensive and are provided as at the date of this Presentation or as of the date specified herein. Certain financial information (including percentages) in this Presentation may have been rounded according to commercial standards. As a result, the aggregate amounts may not correspond in all cases to the aggregated amounts of the underlying (unrounded) figures appearing elsewhere in this Presentation. The financial information presented herein has been prepared in accordance with Swiss GAAP FER. Certain financial data included in this Presentation consists of non-Swiss GAAP FER financial measures. These non-Swiss GAAP FER financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with Swiss GAAP FER. In addition, certain financial information contained herein has not been audited, confirmed or otherwise covered by a report by independent accountants and, as such, actual data could vary, possibly significantly, from the data set forth herein. None of the Company, the Group, and any other person is under any obligation to update or keep current the information contained in this Presentation or to correct any inaccuracies which may become apparent, and any opinions expressed herein are subject to change without notice. Statements made in this Presentation may include forward-looking statements. These statements may be identified by the fact that they use words such as "anticipate", "estimate", "should", "expect", "guidance", "project", "intend", "plan", "believe", "will", "could" and/or other words and terms of similar meaning in connection with, among other things, any discussion of results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. Such statements are based on management's current intentions, expectations or beliefs and involve inherent risks, assumptions and uncertainties, including factors that could delay, divert or change any of them. Forward-looking statements contained in this Presentation regarding trends or current activities should not be taken as a representation that such trends or activities will continue in the future. Actual outcomes, results and other future events may differ materially from those expressed or implied by the statements contained herein. Such differences may adversely affect the outcome and financial effects of the plans and events described herein and may result from, among other things, changes in economic, business, competitive, technological, strategic or regulatory factors and other factors affecting the business and operations of the company. Neither the Company nor any of their subsidiaries or affiliates are under any obligation, and each such entity expressly disclaims any such obligation, to update, revise or amend any forward-looking statements, whether as a result of new information, future events or otherwise. Further, this Presentation may include market share and industry data obtained by the Company from industry publications and market surveys. The Company may not have access to the facts and assumptions underlying the numerical data, market data and other information extracted from public sources and neither the Company, the Group, nor any of their respective directors, officers, employees, shareholders, affiliates, agents and advisers are able to verify such information, and assume no responsibility for the correctness of any such information. This Presentation does not constitute or form part of, and should not be construed as, an offer or invitation or inducement to subscribe for or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Group, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This Presentation does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Neither the Company nor any other member of the Group has registered or intends to register any securities under the Securities Act or the securities laws of any state or other jurisdiction of the United States. THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF THE COMPANY OR THE GROUP. November 2023 SKAN Group AG Investor Presentation 2 SKAN#3Key challenge for (bio-)pharmaceutical products Key challenge: Medical safety Medication safety is key and (cross-) contamination unacceptable Key contamination sources: Air particles Input: Raw materials, containers, closures Personnel Products: Injectables Cancer drugs (ADC, Cytotoxics) Cell & gene therapy (Advanced Therapy Medicinal Products (ATMPS)) Hormones: Insulin Medical drugs (Thrombosis, EPO, blood plasma products, botox, etc.) Vaccines: Flu, COVID-19, etc. November 2023 SKAN Group AG Investor Presentation Increased infection risk as their application bypasses many of the human body's natural defenses A STERILE SLE USE E In particular true for: High-value biopharma drugs Risk of significant economic losses if high-value biopharma drugs get contaminated Risk of cross-contamination increases with small batch size of fast-growing personalized medicine 3 SKAN#4Isolators - Mission critical for (bio-)pharmaceutical processes Solution: Medication sterility Traditional pharma Pharma products mainly chemical based Cleanroom + Filling/closing in cleanroom with terminal sterilization Inappropriate for complex biopharmaceuticals SAL 10-3 Probability of 1 in 1,000 of finding a non sterile unit Raw materials procurement Cleanroom 1 environment Terminal sterilisation Formulation Fill-finish Quality control Packaging & shipping Sterilisation Aseptic processing Biopharma of today and tomorrow New products mainly biotech- based (sensitive to heat and pressure) Isolators Skan + Filling/closing under aseptic conditions eliminating effectively all contamination risk + Reduced cleanroom footprint and running costs and environmental-friendly Complex process results in high market entry barriers November 2023 SKAN Group AG Investor Presentation Note: SAL = Sterility Assurance Level. SAL 10-6 Probability of 1 in 1,000,000 of finding a non sterile unit 4#5SKAN's investment highlights 1 Market leader globally for high-end aseptic process solutions catering the global biopharma industry 2 Technology & innovation 3 leadership with first-to- market solutions and reference point for aseptic manufacturing guidelines xan Strategically positioned in a highly dynamic & rapidly growing niche market driven by strong underlying end market growth 4 Significant barriers to entry due to regulatory requirements know-how and mission criticality of aseptic processes 5 Trusted, long-term partner 6 Experienced & 7 Excellent financial profile 8 to a large, diversified entrepreneurial with demonstrated profitable customer base including almost all major blue-chip (bio-)pharma companies management with proven track record of organic growth above-market growth and solid revenue visibility November 2023 SKAN Group AG Investor Presentation Clear strategy with multiple avenues for growth and expansion of addressable market 5 SKAN#6Global market leader for aseptic process solutions Who is SKAN ? A global market leader in high-end, mission-critical isolator solutions for aseptic and aseptic-toxic production processes across (bio-)pharma Pioneer in the isolator technology with 50+ years of experience in cleanroom equipment Trusted, long-term partner to almost all major blue-chip (bio-)pharma companies Diversified customer base with more than 1,000 total active customers Global footprint across Europe, North America and Asia SKAN aseptic process offering Equipment & Solutions (75%) Customized and standard isolator solutions Automated aseptic filling stations, e.g. for cell & gene therapy Process solution from design & engineering to process qualification SKAN key figures Q-0 -0-0-0-0-0 CHF 277.0m +18.2% CHF 40.2m 14.5% Net sales 2022 Net sales growth 2021-22 EBITDA 2022 EBITDA margin 2022 November 2023 SKAN Group AG Investor Presentation (1) Management estimation of the market share within the premium high-value market. Services & Consumables (25%) → Lifecycle management services Consumables: transfer connectors, closed vials, etc. 50-60% Market share(1) CHF 360.1m Order backlog 2022 6 SKAN#7Product milestones Organizational milestones Longstanding heritage in aseptic manufacturing equipment and processes. Net sales 2022: CHF 277.0m Foundation of Sales & Service office in the US Foundation of SKAN AG as trading company for Scandinavian KAR healthcare equipment In the 1990s, SKAN develops into a manufacturer of isolator equipment BV group BV Holding invests in SKAN as part of a succession financing Acquisition of Hasler Maschinen- und Opening of Sales & Service office in Japan Apparate (today SKAN Stein) Opening of production plant in Germany Skan Acquisition of Hans Meyer Engineering, Swiss integrator of automation and data intelligence New logo SIX IPO at SIX Swiss Exchange 1968 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018 2020 2022 In the 2000s, SKAN pioneers the isolator technology and is mentioned in 2006 as reference in FDA aseptic guidelines Core business November 2023 SKAN Group AG Investor Presentation Acquisition of a 40% stake in Aseptic Technologies, a company specialized in aseptic fill & finish operations (Majority acquisition in 2019) Aseptic technologies Foundation of automated aseptic processing JV with Pharma Integration; Divesture in 2020 and in-house completion of projects Process automation Increase to 85% stake 7 SKAN#8Technology & innovation leadership Fabrication know-how Electron beam transfer Award winning design GMP documentation & qualification of equipment Automation & digitalization expertise November 2023 reddot winner 2021 industrial design Skan spectra SKAN Group AG Investor Presentation HVAC engineering & air flow modelling Chemical know-how on cleaning validation Microbiological & H₂O₂ know-how on surface decontamination Technology leadership & foresight allows SKAN to be the market defining player Continuous active contribution to new guidelines & regulations through industry standards setting organisations (ISPE, PDA, ISO) Pure-play business model enables an undiluted focus of resources to drive technology and innovation More than 1,200 employees globally, of which more than 500 have an academic background, such as scientists and engineers to ensure seamless innovation and production Decontamination cycle down to 3 minutes 8 SKAN#9Highly dynamic niche market with strong end market growth Strong growth of aseptic manufacturing(1) Isolator market by value (EURM) CAGR (2016-20) (20-26F) 2'302 Total 9.3% 11.3% 811 Low value 9.4% 11.8% Key growth drivers Underlying biopharma industry growth: Global pharmaceutical industry: +4.5% p.a. (CAGR 2021-2026F)(2) Cell & gene therapy market: +58% p.a. (CAGR 2020-2024F) (2) Highly potent APIs market: +8.9% p.a. (CAGR 2020-2024F)(2) Shift towards injectable therapies Peptide products by administration route(3): 23% Injection Oral Other 16% 65% 75% 12% Approved / Marketed 9% Pipeline 1'210 414 848 289 796 559 2016A 2020A 1'491 High value 9.2% 11.0% 2026F XXXXX Expected injectable market value growth: +8.5% p.a. (CAGR 2020-2025F)(2) Growth in no. of injectable molecules in development: +17.8% p.a. (CAGR 2014-2020)(2) Shift towards personalized medicine requiring aseptic manufacturing Growing demand for injection administration Growing demand for smaller batch sizes (e.g. expected orphan drug sales growth +10.8% CAGR 2020-2024F(2)) Increased risk of cross-contamination addressed by isolators Continuing trend of pharma outsourcing Increased outsourcing via CMOS is driving the demand for isolation equipment Global CMO market: +6.3% p.a. (CAGR 2020-2025F)(2) November 2023 SKAN Group AG Investor Presentation (1) ེསི་ེ L.E.K. market study. (2) L.E.K. market study based on third-party data. (3) A.N. Ganesh et al, Medicine in Drug Discovery 9 (2021) 100079. 9 SKAN#10Constantly expanding addressable market Aseptic manufacturing market by technology Isolators RABS 0 2015" (1) Cleanroom equipment 0 (1) 2020 0 (2) 2025 Isolator Integrated, fully-automated robotics Shift from cleanroom towards isolator solutions... Key trends DOOX Regulatory environment Personalized medicine Competitive advantages of isolators vs. cleanroom Separation of production process from environment Automated, reproducible, documented bio-decontamination ? Isolator modularity / flexibility ? Reduced cleanroom footprint Lower running costs (energy, quality, etc.) and further to integrated aseptic manufacturing Applications Filling/closing of vials, bottles, pre-filled syringes, IV-bags, inhalers, cartridges Loading/unloading of freeze dryers Sterilisation of tubes November 2023 SKAN Group AG Investor Presentation (1) (2) 2020 ISPE Barrier Survey, August 2020. Based on filling machine orders. Management estimates. 10 SKAN#11Protected market leadership in aseptic processing underpinned by high entry barriers and significant switching costs Market entry barriers SKAN's value proposition Market leadership Technological edge Stringent regulatory environment Mission criticality of aseptic processes Lock-in effect Mastery of difficult to replicate know- how on highest-performance isolators Process warranty regarding all regulatory (e.g. FDA, EMA, Swissmedic) required qualifications & timeline Swiss brand, engineering & reputation provide trust in isolator safety Large installed base of isolators and leading global services incl. tech transfer & consumables across product lifecycle November 2023 SKAN Group AG Investor Presentation Z OPTIMA REINRAUMTECHNIK IMA SPA Skan SYNTEGON PROCESSING & PACKAGING La Calhène vanr Pharmasystems Inc. 11 SKAN#12Trusted, long-term partner for global (bio-)pharma customers gsk novo nordisk Johnson & Johnson MERZ Lilly Number of clients 2020 21% Lonza Selected (bio-)pharma customers... Key statistics High level of recurring customers Number of clients & order intake share by type of client(1) 20% 10% 00 60% 30% Order intake 2020 59% Loyal customers Share of top 50 customers over 2012-2020 contributing to 75% of total order intake over last 9 years (1) 14% Top 50 clients 2012-2020 86% Baxter moderna™ Roche SANOFI NOVARTIS Recurring customers (2018-2020) New clients (2019 & 2020) Opportunistic clients Limited customer concentration Total order intake 2018-2020 per customer(2) Recurring clients (Continuous new order intake) New clients (First order intake) Large exposure to biopharma market Total order intake 2018-2020 per end market (2)(3) abbvie GILEAD 24% 15% 17% 43% 81% 4% 14% Pfizer Takeda November 2023 SKAN Group AG Investor Presentation (1) (2) 723 ■Top 1-5 ■Top 6-10 ■Top 11-20 Rest (Bio-)pharma ■CMO Cell & Gene Analysis based on customers of SKAN AG (SKAN AG includes almost all of SKAN's projects while Service & Consumables may be ordered on the local subsidiary level). Analysis based on customers of SKAN AG and Aseptic Technologies. (3) Analysis based on management estimates and suffers from limited customer disclosure on actual use of SKAN's equipment. (Bio-)pharma includes Pharma and Vaccines. Customers of Aseptic Technologies classified as Cell & Gene (or CMO if a clear distinction can be made). 12 SKAN#13Equipment & Solutions ("E&S") 75% of revenue Services & Consumables ("S&C") 25% of revenue Comprehensive portfolio for aseptic manufacturing processes Cleanroom Pure Solutions Pure Solutions Trading Customized and modular isolators Business contrib. Process Solutions Trading of Laboratory/ cleanroom equipment, mostly in Switzerland Horizontal/verti- cal workbenches Fume cupboards Particle counters Customized Solutions ("CusSol") Customer-specific isolator solutions for aseptic manufacturing and filling Process warranty incl. complete GMP compliance Business contrib. System Solutions ("SysSol") Modular isolators equipped flexibly with process tools Close collaboration with process tool partners Integrated processes Integrated Process Solutions Aseptic Technologies (AT) Proprietary, automated closed-vial filling equipment for small/medium-batch cell & gene therapy integrated within isolator Process Automation Global process solution Business contrib. providing automated (robotic) process handling fully integrated within the isolator Services Qualification Consumables Personal protective equipment Biosanitizer Consumables Biological Indicator Electron Beam (bulbs) Spares (gloves, filters, etc.) Services Life cycle support GMP requalification Performance studies Consumables Closed vials Connectors Filling kits Services November 2023 SKAN Group AG Investor Presentation Rent a machine Life cycle support Consumables Refer to process consumables Services Refer to process services Digital integration into MES(1) and ERP systems 13 SKAN#14Product lifecycle Time One-stop-shop across the entire lifecycle of SKAN's mission- critical aseptic process solutions Year 0 (0.5y) Year 1-2 Year 2-3 Design & engineering Year 2-20 Year 20 Value-creation(1): Approx. 5-10% Design: Close collaboration with customers and other equipment suppliers for process conceptualization Engineering: Development of customer-specific process solutions Scientific studies Digitalization: full data integration Manufacturing & assembling Value-creation(1): Approx. 80% In-house production and assembly Customer approval (FAT) Transport, assembly & commissioning Personal user training Operational warranty Commissioning & qualification Global lifecycle support End-of-life services Value-creation(1): Approx. 10-15% Installation & operational qualification incl. GMP- compliant documentation Microbiological monitoring incl. GMP- compliant documentation Cleaning qualification Regulatory compliance support Process warranty Scheduled checks & preventive maintenance Repair & spare parts Re-qualifications (IQ/OQ, microbiological qualification) System upgrades Relocation System upgrades End of life disposal Global installed base of Approx. 1'000 SKAN isolators (incl. E-Beam) Approx. 400 AT filling solutions More than 10,000 lab equipment November 2023 SKAN Group AG Investor Presentation (1) Value creation is an approximation for the value-add provided in each step in a typical project of an isolator process solution for a client and is based on SKAN's Percentage-of-Completion method for invoicing clients throughout the project. The Percentage-of-Completion for milestones vary from project to project and should be considered as indicative approximation only. 14 SKAN#15SKAN Aseptic Technologies is of strategic importance for SKAN Five AT filled drugs on the market: Customer Janssen Daiichi-Sankyo Product area Oncolytic virotherapy for brain cancer Phase Boehringer Ingelheim Cartilage repair for veterinary applications Oncology * Lentivirus used for the production of a drug against multiple myeloma PHARMACEUTICAL COMPANIES OF Johnson-Johnson LEGEND BIOTECH ATARA BIO Monotherapy for the treatment of Epstein-Barr virus Treatment of wounds in patients with Krystal dystrophic epidermolysis bullosa in collagen type VII alpha 1 chain gene Aseptic Technologies (AT) provides automated, robot- assisted process solutions for polymer closed vials (AT- Closed VialⓇ Technology) for applications in cell and gene therapy, a market segment that is growing +58% p.a. (CAGR 2020-2024)(1). Injection molded AT-Closed Vials® are suitable for cryogenic storage at temperatures down to -196 c, which is not possible with glass vials and is a unique selling point There are now five drugs on the market that are filled using the closed vial solution of AT. The development pipeline of drugs is in the range of approx. 400 active ingredients. SKAN increased its stake in AT to 85% and is strengthening its Services & Consumables business, fully in line with our long-term strategy. November 2023 SKAN Group AG Investor Presentation (1) L.E.K. market study based on third-party data. 15#16Strong and growing global footprint Allschwil CH Headquarters / production sites • • Engineering, sales, service, assembly, R&D, laboratories Approx. 26,682 m² 678 employees Stein CH Production site • • Prototype construction, steelwork, E-Beam competence Approx. 6,923 m² 118 employees skán Skan skan Görlitz DE Production site Skan • Focus: Steelwork, production, assembly, qualification • Approx. 26,649 m² • 291 employees Skan Skan Headquarter Raleigh US Gembloux BE Gembloux BE Görlitz DE • Allschwil CH Stein CH Okinawa JP SKAN Locations • November 2023 SKAN Group AG Investor Presentation Production site / AT • Aseptic Filling equipment (Closed VialⓇ Technology) Approx. 3,590 m² 43 employees Raleigh US Sales & services office Sales and life cycle support Americas Approx. 1,200 m² 97 employees Okinawa JP Production site • Sales, assembly, and life cycle support Far East Approx. 2,170 m² • 42 employees Skan ASEPTIC 16 SKAN N N#17Experienced, entrepreneurial management and highly qualified workforce loyal to the firm Dedicated workforce Board of Directors Loyal, increasing workforce (1) 1'172 371 203 56.7% 71.7% 2010 2015 Headcount 77.7% 2022 ■Headcount still with SKAN today Low employee turnover (2) Dr. Gert Thoenen Dr. Beat Lüthi Chairman Cornelia Gehrig Gregor Plattner Oliver Baumann Patrick Schär Thomas Huber Vice Chairwoman Experienced management team >70 combined years at SKAN approx. 180 combined years in the industry Thomas Huber 658 CEO 25+ Burim Maraj CFO 18+ Ralf Krämer CTO 36+ 575 498 400 334 5.4% Philippe Jérôme 6.3% 4.2% 4.0% 3.7% CMO 20+ Marina Häni CPCO 8+ Dr. Sascha Pawel CIO 11+ 2018 2019 2020 2021 2022 FTES SKAN AG % turnover November 2023 Martin Steegmüller CPO & CDO 19+ Thomas Zinn Maria Cuevas Otero CCO 17+ CSO 22+ Years of industry experience SKAN Group AG Investor presentation (1) All figures as of December of respective year and exclusive of temporary workers. (2) Refers to SKAN AG. 17 SKAN#18Highlights of the first half year 2023 Order Intake in CHF million Net Sales in CHF million 175.3 -33.4% (1) EBITDA in CHF million 18.6 +74.1%(1) Investments in CHF million 10.2 -35.1%(1) 139.7 +15.6% (1) EBITDA-Margin as % of Net Sales 13.3 +4.5pp(1, 3) Order Backlog in CHF million 384.6 +6.8% (2) Record high order backlog and book-to-bill ratio at 1.3 provide good visibility. Order intake normalized at a continued high level in the first six months of 2023. Overall, the order pipeline remains well-filled. Double digit net sales growth within guidance. EBITDA significantly increased compared to the same period last year. EBITDA-Margin withing guidance. EBIT more than doubled from CHF 5.9 million to CHF 12.4 million. Total investments of CHF 10.2 million mainly related to Pre- Approved Services project. November 2023 SKAN Group AG Investor Presentation (1) Changes compared to 1st half 2022 (2) Changes compared to 31.12.2022 (3) Percentage points N N SKAN 19#19Century of biology: Shift toward injectable biotech drugs drives need for aseptic process solutions Top 10 medicines 2005 Top 10 medicines 2020 Phzer Lipitor 40 mg film-coated tablets Atorvastatin Lipitor Pfizer Zoloft 50 mg Sa 30 Fimtabletsan Zoloft Pfizer 40 mg 28 fm-coa Calandar pack Nexium 10 Nexium Astra Zeneca Treats Frequent Heartbur 24HR PREVACID 42 Zocor 80 mg 28 Tabletter/Comprimés ADVAIR Plavix.75 mg Clopidogrelum Plavix Prevacid Takeda Efexor ER 150 mg Venta um Lipitor Pfizer MSD SINGULAIR 10mg Fablemen Comprimés times MED SANOFI5 Sanofi Efexor Pfizer NDC 61755-005-02 EYLEA (aflibercept) Injection For Intravitreal Injection 2 mg/0.05 mL Single-use Vial Keytruda (pembrolizumab) for Injection 50mg/vial NOC 14 Revlimid eraldonide cap 25 mg Singulair MSD Eliquis. (apixabar tablets 5 mg Adavair Diskus GSK Pfizer Norvasc 5 mg Amlodipin Norvasc MSD November 2023 SKAN Group AG Investor Presentation Imbruvica 120 Cap 100 Cap EYLEA Eliquis BONLY SKAN Eylea Regeneron, Bayer 2020 Sales: $8.36 Mia. Keytruda Merck & Co. 2020 Sales: $14.38 Mia. Revlimid Bristol Myers Squibb 2020 Sales: $12.15 Mia. Eliquis Bristol Myers Squibb, Pfizer 2020 Sales: $9.17 Mia. Imbruvica AbbVie, Johnson & Johnson 2020 Sales: $8.43 Mia. HUMIRA PEN adalimumab 40 mg/0.4m Stelara Esteknum 130mg/26 m (5 mph) Humira AbbVie 2020 Sales: $20.39 Mia. Stelara Johnson & Johnson 2020 Sales: $7.94 Mia. Opdivo Opdivo notma Biktarvy nog sir, emtricitabine and we alafenamide) cabin 53 mg/200/25 Xarelto (rivaroxaban) Tablets 10 mg Opdive Opdivo Bristol Myers Squibb 2020 Sales: $7.92 Mia. Biktarvy Gilead Sciences 2020 Sales: $7.26 Mia. Xarelto Bayer, Johnson & Johnson 2020 Sales: $6.93 Mia. mAb / biotech drug substance 21#20Confident market and business outlook Demand momentum in our market is expected to continue at a high level. Main drivers are: → The underlying growth of the global (bio)pharmaceutical market; →The reinforcing trend towards injectable drugs (three quarters of the drugs in development are now designed for an injectable dosage form); The shift from traditional cleanrooms to the technologically more advanced isolator technology; The reshoring of pharmaceutical production. As a consequence, demand for SKAN's equipment, services and consumables will continue, as evidenced by the well-filled order pipeline. To accommodate the strong growth, we will - besides North America - further expand production capacity at the existing sites in Switzerland and Germany. SKAN Group expects the 2nd half of 2023 to be even stronger than the 1st half in terms of net sales and profitability. Guidance for the full year 2023 confirmed. November 2023 SKAN Group AG Investor Presentation SKAN 22 22#21Financial targets and outlook Metric Group net revenue growth Segment net revenue growth (2) EBITDA margin November 2023 SKAN Group AG Investor Presentation 2023 Targets (1) Mid- to upper teens E&S S&C 13-15% Mid-Term Outlook Mid- to upper teens E&S S&C Gradually increase profitability level to upper teens in the mid-term. Potential for further increase beyond mid-term period. (1) 2023 targets assume no further deterioration (direct or indirect) of supply chain conditions and other unpredictable development of the geopolitical situation. (2) E&S refers to Equipment & Solutions. S&C refers to Services & Consumables. 72 23 SKAN#22Business units Clear growth strategy 1 2 Fortify market leadership Expand addressable market towards integrated process systems " Investment in production capacity expansion and scale-up Continuous innovation to meet customer's demand and to maintain technical leadership Continuous active contribution to new guidelines & regulations Grow service revenues with ever- increasing installed base of isolators ☐ Scale-up of Aseptic Technologies Intensified joint developments with established fill-finish partners In-house development of automated process equipment in combination with isolator technology Integrated Process Solutions Services Consumables Process Solutions November 2023 SKAN Group AG Investor Presentation ◉ ■ ☐ Objectives: Continue growth track-record Increase recurring revenue base Expand profitability 3 4 Increase exposure to after- market services & consumables revenues Accelerate digital transformation Increasing, global product lifecycle support with expanding installed base of isolators Further development of innovative consumables (e.g. closed vials, transfer systems, filling kits) Additional service offerings of "pre-approved" solutions to help customers shorten time-to-market New financing models such as pay per use and off the shelf delivery Services & Consumables ■ ■ Increased augmented reality service support to increase reaction time and reduce long distance travel Increased Virtual Reality design support Industry 4.0 - - Artificial Intelligence for preventive maintenance "One button release" paperless GMP compliant documentation All Equipment & Solutions. Services & Consumables. 24 24 SKAN#23% of total SKAN is committed to invest significantly in its core business and in future growth Investment split Expansion of production capacity General corporate purposes and M&A Planned investments over the mid-term 2022 2023 November 2023 SKAN Group AG Investor Presentation CHF 100-120m Growth capex Build-up of a pre- approved/pay-per- use service business 100% SKAN will use the proceeds from the IPO as well as cash generated from operations to Expand the production capacity to strengthen the core business Further build up of the company's services business General corporate purposes and opportunistic M&A opportunities SKAN plans to invest into pre-approved / pay-per-use service business These pre-approved services are expected to deliver attractive EBITDA margins of up to 50% 2024 2025 Total 25 S#24Together always one step ahead! NI N SKAN Skan 26